Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $\begin{array}{l} Introduced \ 01/07/96 \ \ Origin: Appendix \ 5 \ \ Amended \ 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13 \end{array}$

Name of entity

Skyfii Limited

ABN

20 009 264 699

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 *Class of *securities issued or to be issued
- Fully paid shares paid to Directors in lieu of Directors Fees (Directors Shares)
- Employee Share Plan (ESP), Non-Directors
- 3. Executive Option Plan (EOP), Executive Director
- Executive Option Plan (EOP), Non-Director
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 1. 1,500,000 Directors Shares
- 2. 8,500,000 Employee Share Plan
- 3. 4,675,237 Executive Option Plan
- 4. 16,037,184 Executive Option Plan
- 3 Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)
- Fully paid ordinary shares, equally quoted with SKF
- ESP in accordance with Company's ESP subject to vesting conditions, equally quoted with SKF
- 3&4. EOP in accordance with Company's EOP subject to vesting conditions, unquoted

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Refer 3 above
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment	
	the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	 Directors Fees in lieu of cash payments at: \$0.16 per share Employee Share Plan: \$0.16 per share Executive Option Plan: \$0.01 per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	 Pursuant to shareholder approval at 2019 AGM held on 12th November 2019. 2,3 & 4. Issued to staff as apart of agreed remuneration agreements and pursuant to shareholder approval at 2019 AGM held on 12th November 2019.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	12 November 2019
6c	Number of *securities issued	N/A
	without security holder approval under rule 7.1	,

Appendix 3B Page 2 04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer Schedule	
7	⁺ Issue dates	25 November 2019	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	23 NOVERIDEI 2017	
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	283,055,017	Fully Paid Ordinary Shares

⁺ See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
4,580,000	2015 ESP Shares. Various vesting
	dates.
1,825,000	2016 ESP Shares. Various vesting
	dates.
2,000,000	Unquoted Directors Options, various
	exercise prices
12,703,000	2016 ESP Shares. Various vesting
	dates.
800,000	2017 ESP Shares. Various vesting
,	dates.
6,000,000	2017 ESP Shares. Various vesting
-,,	dates.
11,100,000	2018 ESP Shares. Various vesting
11,100,000	dates.
2,500,000	autes.
2,500,000	Unquoted Options. Various
600.000	vesting dates.
600,000	Unquoted Directors Options,
0.0	various Exercise prices
18,835,571	2018 Executive Option Plan.
	various vesting dates.
6,190,475	2019 Unquoted Options at \$.021
	exercise price.
8,500,000	2019 ESP Shares. Various vesting
-,,,,	dates.
	2019 Executive Option Plan.
20,712,421	various vesting dates.
	various vesting dates.
i e	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

11	Is	security	holder	approval
	req	uired?		

N/A

12 Is the issue renounceable or non-renounceable?

N/A

13 Ratio in which the ⁺securities will be offered

N/A

14 +Class of +securities to which the offer relates

N/A

15 *Record date to determine entitlements

N/A

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32		y holders dispose ments (except by roker)?	N/A	
33	⁺ Issue date		N/A	
	-	on of securit	ties plying for quotation of securities	
34	Type of *securit (tick one)	ies		
(a)	*Securitie	es described in Part	:1	
(b)	Example: re		end of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible	
Entities that have ticked box 34(a)				
Addit	ional securitie	s forming a new	class of securities	
Tick to docume		roviding the informat	cion or	
35	additiona		securities, the names of the 20 largest holders of the the number and percentage of additional *securities	
36		es setting out the nu 000 0,000 100,000	y securities, a distribution schedule of the additional umber of holders in the categories	
37	A copy of	any trust deed for	the additional ⁺ securities	

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
20	⁺ Class of ⁺ securities for which		
39	quotation is sought		
40	Do the teacurities rank equally in		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:		
	 the date from which they do the extent to which they 		
	participate for the next dividend, (in the case of a trust, distribution) or interest		
	paymentthe extent to which they do not		
	rank equally, other than in relation to the next dividend,		
	distribution or interest payment		
41	Reason for request for quotation		
	now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another +security, clearly identify		
	that other ⁺ security)		
40	Number and taless of all	Number	+Class
42	Number and +class of all +securities quoted on ASX		
	(including the ⁺ securities in clause		
	38)		

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the

 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 25 November 2019

(Company secretary)

Print name: Ms Koreen White

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	275,626,289		
Add the following:	1,428,572 (Shareholder approved FPO shares, 3B dated 28 December 2018)		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	7,500,000 (Shareholder approved ESP shares, 3B dated 28 December 2018)		
Number of fully paid ⁺ ordinary securities issued in that 12 month period with	16,943,289 (Shareholder approved EOP shares, 3B dated 28 December 2018)		
shareholder approval	1,892,282 (Shareholder approved EOP shares, 3B dated 21 January 2019)		
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	1,365,000 (Shareholder approved Directors Options converted to FPO, 3B		
Note:	dated 3 April 2019)		
Include only ordinary securities here – other classes of equity securities cannot be added	1,272,727 (Shareholder approved Directors Options converted to FPO, 3B dated 9 April 2019)		
Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed	1,500,000 (Shareholder approved FPO shares, 3B dated 25 November 2019)		
It may be useful to set out issues of securities on different dates as separate line items	8,500,000 (Shareholder approved ESP shares, 3B dated 25 November 2019)		
	20,712,421 (Shareholder approved EOP shares, 3B dated 25 November 2019)		
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	О		
"A"	336,740,580		

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	50,511,087
Step 3: Calculate "C", the amount that has already been used	of placement capacity under rule 7.
Insert number of +equity securities issued	335,730 share: Appendix 3B 25072018
or agreed to be issued in that 12 month period <i>not counting</i> those issued:	98,926 share: Appendix 3B 12092018
• Under an exception in rule 7.2	75,000 share: Appendix 3B 08102018
Under rule 7.1A	2,500,000 options: Appendix 3B21112018
 With security holder approval under rule 7.1 or rule 7.4 	6,190,475 options: Appendix 3B22052019
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	2,500,000 shares: Appendix 3B 09072019
"C"	11,700,131
Step 4: Subtract "C" from ["A" x "L placement capacity under rule 7.1	B"] to calculate remaining
"A" x 0.15	50,511,087
Note: number must be same as shown in Step 2	
Subtract "C"	11,700,131
Note: number must be same as shown in Step 3	
Total ["A" x 0.15] – "C"	38,810,956
	[Note: this is the remaining placement capacity under rule 7.1]

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Step 1 of Part 1 Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	33,674,058	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		

"E"

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	33,674,058	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"	33,674,058	
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.